American Regent’s US Food and Drug Administration approved 505(b)(2) hybrid new drug application product referencing Endo International’s Vasostrict (vasopressin) is a puzzle for investors – and it appears to be one for recent ANDA recipient Eagle Pharmaceuticals, as well, as it looks to make good on its award of 180 days of generic market exclusivity.
Endo had “mentioned that one of the parties that they had settled with filed through the 505(b)(2) process, and they’re...




